Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1423-1431

  Linderholm, Barbro ^a   Grankvist, Kjell ^a   Wilking, Nils ^a   Johansson, Mikael ^a   Tavelin, Björn ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION;

EID: 0034034667     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1423     Document Type: Article

References (43)

1. Veronesi U, Luini A, Galimberti V, et al: Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 16:127-133, 1990
2. Fentiman IS, Mansel RE: The axilla: Not a no-go zone. Lancet 1:221-223, 1991
3. Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983
4. Bonnadonna G, Valagussa P: Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3:259-275, 1985
5. Hendersson IC, Harris JR, Kinne DW, et al: Cancer of the breast, in DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, pp 1230-1235
6. Gasparini G, Pozza F, Harris AL: Evaluating usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
7. Mason BH, Holdaway IM, Mullins PR, et al: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43:2985-2990, 1983
8. Clark GM: Should selection of adjuvant chemotherapy for patients with breast cancer be based on erb-2 status? J Natl Cancer Inst 90:1320-21, 1998
9. Cattoretti G, Rilke F, Andreola S, et al: P53 expression in breast cancer. Int J Cancer 41:178-183, 1988
10. Silvestrini R, Veneroni S, Benini E, et al: Expression of p53 in node-negative breast carcinoma. J Natl Cancer Inst 16:965-970, 1993
11. Thor A, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancer. J Natl Cancer Inst 11:845-855, 1992
12. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
13. Bergh J, Norberg T, Sjögren S, et al: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 10:1029-1034, 1995
14. Borg Å, Lennerstrand J, Stenmark-Askmalm M, et al: Prognostic significance of p53 overexpression in primary breast cancer: A novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71:1013-1017, 1995
15. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
16. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
17. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer. Lancet 340:1120-1124, 1992
18. Bosari S, Lee AKC, De Lellis RA, et al: Microvessel quantification and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
19. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993
20. Fox SB, Leek RD, Smith K, et al: Tumor angiogenesis in node-negative breast carcinomas: Relationship with epidermal growth factor receptor and survival. Breast Cancer Res Treat 29:109-116, 1994
21. Obermair A, Czerzwenka K, Kurz C, et al: Influence of tumoral microvessel density on the recurrence-free survival in human breast cancer: Preliminary results. Onkologie 17:44-49, 1994
22. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
23. Toi M, Inada K, Suzuki H, et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Cancer Res Treat 36:193-204, 1995
24. Heimann R, Ferguson D, Powers C, et al: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 23:1764-1769, 1996
25. Gasparini G, Toi M, Gion M, et al: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997
26. Leung DW, Cachianes G, Kuang WJ, et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
27. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
28. Dvorak HF: Tumours: Wounds that do not heal-Similarity between tumour stroma generation and wound healing. N Engl J Med 315:1650-1658, 1983
29. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-859, 1989
30. Unemori EN, Ferrara N, Bauer EA, et al: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153:557-562, 1992
31. Lindgren M, Johansson M, Sandström J, et al: VEGF and tPA co-expressed in malignant glioma. Acta Oncologica 6:615-618, 1997
32. Linderholm B, Tavelin B, Grankvist K, et al: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121-3128, 1998
33. Toi M, Kondo S, Suzuhi H, et al: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77:1101-1106, 1996
34. Scott PAE, Smith K, Poulsom R, et al: Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 12:2120-2128, 1998
35. Gasparini G, Barbareshi M, Boracchi P, et al: Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J 1:131-141, 1995
36. Kolch W, Martiny-Baron G, Kieser A, et al: Regulation of the expression of the VEGF/VPS and its receptors: Role in angiogenesis. Breast Cancer Res Treat 36:139-155, 1995
37. Gagliardi A, Collins DC: Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533-535, 1993
38. Noguchi S, Motomura K, Inaji H, et al: Down regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer 72:131-136, 1993
39. Antonelli-Orlidge A, Saunders KB, Smith SR, et al: An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86:4544-4548, 1989
40. Cordon-Cardo C, O'Brian JP, Boccia J, et al: Expression of the multidrug resistence gene product P-glycoprotein in human normal and tumor tissues. J Histochem Cytochem 9:1277-1287, 1990
41. Terrier P, Townsend AJ, Coindre JM, et al: An immunohistochemical study of Pi class gluthatione S-transferase expression in normal human tissues. Am J Pathol 137:845-853, 1990
42. Yoshiji H, Harris SR, Thorgeirsson: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57:3924-3928, 1997
43. Gasparini G, Toi M, Miceli R, et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5:101-111, 1999